| Species |
Human |
| Protein Construction |
NTS1 (Ser24-Leu163)_x000D_
Accession # P30990 |
hFc |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized NTS1 hFc Chimera, Human at 5μg/ml (100μl/well) on the plate can bind Biotinylated AntiNTS Antibody, hFc Tag. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
42.9 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 48-53 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Neurotensin (NT) is an endogenous 13 amino acid neuropeptide with profound opioid-independent analgesic effects. This role of NT is thought to be mediated by both neurotensin receptor subtype 1 (NTS1) and neurotensin receptor subtype 2 (NTS2). NT and its receptors are widely distributed in the pain circuits in central nervous system. |
| Synonyms |
NT; NTR; NTR1; NTRH; NTRR; NTS1; NTSR1; NMN-125; NN; NT/N; NTS; Neurotensin/neuromedin N; Neurotensin |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
